IV Ciprofloxacin-Induced Phlebitis: Investigating the Impact of Pharmaceutical and Process-Related Factors on Patient Safety
,
Abstract
Transient phlebitis is a rare but notable adverse reaction that can occur following intravenous administration of various medications, including ciprofloxacin, an antibiotic recognized for its broad-spectrum activity. This case report discusses a 48-year-old male patient with poorly controlled type 2 diabetes who developed phlebitis after receiving undiluted ciprofloxacin via a peripheral intravenous line. Symptoms emerged within 24 hours, characterized by swelling and redness at the injection site, prompting the discontinuation of the medication. Analysis revealed that improper dilution and rapid infusion rate were major factors contributing to the development of phlebitis. This underscores the importance of adhering to guidelines provided in product information leaflets for intravenous drug preparation and administration. The case emphasizes the critical need for healthcare professionals to follow recommended protocols to reduce the risk of infusion-related complications, especially in patients with underlying comorbidities.
2. Ballesteros-Peña S, Fernández-Aedo I, Vallejo-De la Hoz G, Tønnesen J, Miguelez C. Identification of potentially irritating intravenous medications. Enfermería Intensiva (English ed.). 2022;33(3):132-40.
3. Manchegowda SN, Zbeidy R, Souki FG. Transient phlebitis: an unusual effect of intravenous diphenhydramine. BMJ Case Rep. 2020;13(7):e237273-.
4. Lanbeck P, Odenholt I, Paulsen O. Antibiotics differ in their tendency to cause infusion phlebitis: a prospective observational study. Scand J Infect Dis. 2002;34(7):512-9.
5. Heng SY, Yap RT, Tie J, McGrouther DA. Peripheral vein thrombophlebitis in the upper extremity: a systematic review of a frequent and important problem. Am J Med. 2020;133(4):473-84.
6. Lv L, Zhang J. The incidence and risk of infusion phlebitis with peripheral intravenous catheters: A meta-analysis. J Vasc Access. 2020;21(3):342-9.
7. Rao A, Patil D, Thyagaraj V, Shankar SH, Balawat A. Transient reactive phlebitis and intravenous ciprofloxacin: Is there an association?. BMJ Case Rep. 2023;16(10):e254289.
8. Azimi-Ghomi O, Napier A. Getting Under Your Skin: First Reported Case of Transient Reactive Phlebitis Involving Vancomycin Infusion Therapy. Cureus. 2021;13(10).
9. Shah A, Ong PY. Immediate superficial venous thrombophlebitis associated with intravenous administration of ciprofloxacin. J Pediatr. 2018;200:289.
10. Bayer HealthCare Pharmaceuticals Inc. CIPRO IV (Ciprofloxacin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/019857Orig1s073lbl.pdf . Revised March 2022.
11. Nord CE, Norrby SR. Changing trends in antibiotic therapy: role of ciprofloxacin. Scand J Infect Dis. 1988;20(sup60):1-28.
12. Sharma PC, Jain A, Jain S, Pahwa R, Yar MS. Ciprofloxacin: review on developments in synthetic, analytical, and medicinal aspects. J Enzyme Inhib Med Chem. 2010;25(4):577-89.
13. Appelbaum PC, Hunter PA. The fluoroquinolone antibacterials: past, present and future perspectives. Int J Antimicrob Agents. 2000;16(1):5-15.
14. de Almeida MV, Saraiva MF, de Souza MV, da Costa CF, Vicente FR, Lourenço MC. Synthesis and antitubercular activity of lipophilic moxifloxacin and gatifloxacin derivatives. Bioorg Med Chem Lett. 2007;17(20):5661-4.
15. Mertzlufft F, Brettner F, Crystal GJ, et al. Intravenous fluids: issues warranting concern. Eur J Anaesthesiol. 2022;39(4):394-6.
16. Armbruster C, Robibaro B, Griesmacher A, Vorbach H. Endothelial cell compatibility of trovafloxacin and levofloxacin for intravenous use. J Antimicrob Chemother. 2000;45(4):533-5.
| Files | ||
| Issue | Vol 11, No 3 (Summer 2024) | |
| Section | Case Report(s) | |
| Keywords | ||
| Thrombophlebitis; Pharmacovigilance; Adverse drug reaction | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
